These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24853185)

  • 1. Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells.
    Mancini M; Gariboldi MB; Taiana E; Bonzi MC; Craparotta I; Pagin M; Monti E
    Br J Cancer; 2014 Jun; 110(12):2865-73. PubMed ID: 24853185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-Targeting IGF-1R and Autophagy Enhances the Effects of Cell Growth Suppression and Apoptosis Induced by the IGF-1R Inhibitor NVP-AEW541 in Triple-Negative Breast Cancer Cells.
    Wu W; Ma J; Shao N; Shi Y; Liu R; Li W; Lin Y; Wang S
    PLoS One; 2017; 12(1):e0169229. PubMed ID: 28046018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis.
    Moser C; Schachtschneider P; Lang SA; Gaumann A; Mori A; Zimmermann J; Schlitt HJ; Geissler EK; Stoeltzing O
    Eur J Cancer; 2008 Jul; 44(11):1577-86. PubMed ID: 18445520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer.
    Hamilton N; Austin D; Márquez-Garbán D; Sanchez R; Chau B; Foos K; Wu Y; Vadgama J; Pietras R
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29099049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.
    Esparís-Ogando A; Ocaña A; Rodríguez-Barrueco R; Ferreira L; Borges J; Pandiella A
    Ann Oncol; 2008 Nov; 19(11):1860-9. PubMed ID: 18641009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas.
    Piao W; Wang Y; Adachi Y; Yamamoto H; Li R; Imsumran A; Li H; Maehata T; Ii M; Arimura Y; Lee CT; Shinomura Y; Carbone DP; Imai K
    Mol Cancer Ther; 2008 Jun; 7(6):1483-93. PubMed ID: 18566219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression.
    Mukohara T; Shimada H; Ogasawara N; Wanikawa R; Shimomura M; Nakatsura T; Ishii G; Park JO; Jänne PA; Saijo N; Minami H
    Cancer Lett; 2009 Sep; 282(1):14-24. PubMed ID: 19345478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.
    Höpfner M; Huether A; Sutter AP; Baradari V; Schuppan D; Scherübl H
    Biochem Pharmacol; 2006 May; 71(10):1435-48. PubMed ID: 16530734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
    Friedrichs N; Küchler J; Endl E; Koch A; Czerwitzki J; Wurst P; Metzger D; Schulte JH; Holst MI; Heukamp LC; Larsson O; Tanaka S; Kawai A; Wardelmann E; Buettner R; Pietsch T; Hartmann W
    J Pathol; 2008 Dec; 216(4):428-39. PubMed ID: 18855347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours.
    Höpfner M; Baradari V; Huether A; Schöfl C; Scherübl H
    Endocr Relat Cancer; 2006 Mar; 13(1):135-49. PubMed ID: 16601284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells.
    Gariboldi MB; Ravizza R; Monti E
    Biochem Pharmacol; 2010 Aug; 80(4):455-62. PubMed ID: 20488164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line.
    Ekyalongo RC; Mukohara T; Kataoka Y; Funakoshi Y; Tomioka H; Kiyota N; Fujiwara Y; Minami H
    Invest New Drugs; 2013 Apr; 31(2):293-303. PubMed ID: 22828916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award.
    Whitson BA; Jacobson BA; Frizelle S; Patel MR; Yee D; Maddaus MA; Kratzke RA
    Ann Thorac Surg; 2006 Sep; 82(3):996-1001; discussion 1001-2. PubMed ID: 16928523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
    Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
    Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
    Maiso P; Ocio EM; Garayoa M; Montero JC; Hofmann F; García-Echeverría C; Zimmermann J; Pandiella A; San Miguel JF
    Br J Haematol; 2008 May; 141(4):470-82. PubMed ID: 18341634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.
    Gotlieb WH; Bruchim I; Gu J; Shi Y; Camirand A; Blouin MJ; Zhao Y; Pollak MN
    Gynecol Oncol; 2006 Feb; 100(2):389-96. PubMed ID: 16300820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL.
    Pennarun B; Kleibeuker JH; Oenema T; Stegehuis JH; de Vries EG; de Jong S
    Cell Oncol (Dordr); 2011 Jun; 34(3):245-59. PubMed ID: 21538027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Picropodophyllin inhibits proliferation and survival of diffuse large B-cell lymphoma cells.
    Strömberg T; Feng X; Delforoush M; Berglund M; Lin Y; Axelson M; Larsson O; Georgii-Hemming P; Lennartsson J; Enblad G
    Med Oncol; 2015 Jul; 32(7):188. PubMed ID: 26021470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.
    Gao J; Chesebrough JW; Cartlidge SA; Ricketts SA; Incognito L; Veldman-Jones M; Blakey DC; Tabrizi M; Jallal B; Trail PA; Coats S; Bosslet K; Chang YS
    Cancer Res; 2011 Feb; 71(3):1029-40. PubMed ID: 21245093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells.
    Ioannou N; Seddon AM; Dalgleish A; Mackintosh D; Modjtahedi H
    BMC Cancer; 2013 Jan; 13():41. PubMed ID: 23367880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.